ABEO (39) AMRN (43) QTTB (61) BCYC (24) ⌘ Pro Terminal →

Immuneering Corporation (Class A) (IMRX) — RQD Stock Rating Cockpit

$4.02 +0.75% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Immuneering Corporation (Class A) (IMRX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $260.1M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMRX)Realized 20D OHLCV Swing Band: ±12%

RSI-14 MOMENTUMNEUTRAL RANGE

43.130 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE13% OF RANGE

L: $3$4.02H: $8

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 15 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on IMRX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and -17.49% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (45)

15/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like IMRX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMRX)

✓Walkthrough of IMRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IMRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.28%⚡ TESTING RESISTANCE

2026-10-30O $4.01H $4.07L $3.72C $4.02VOL 1.14M

RES: $4.11SUP: $3.25SMA50: $4.28SMA200: $4.81

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMRX Butterfly Map → + Track IMRX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IMRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IMRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMRX)

Health Care Rank #481 of 1016 ⚔️ ABEO vs IMRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMRX vs. ABEO, AMRN, QTTB, BCYC)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Immuneering Corporation (Class A) (IMRX) ranks #481 by composite RQD confidence (45/100, grade D) and #542 by equity capitalization ($260.1M). Within this direct 5-issuer industry benchmark cohort, QTTB leads on earnings valuation at 8.9x trailing P/E, while QTTB leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. QTTB currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with IMRX at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IMRX ACTIVE Immuneering Corporation (Class A)	D	45/100	—	—	-35.0%	+0.75%	$260.1M	Benchmark Subject
ABEO Abeona Therapeutics Inc.	D-	39/100	—	73.7%	-35.0%	+0.22%	$260.8M	/abeo-vs-imrx →
AMRN Amarin Corporation plc	D-	43/100	—	56.6%	-12.2%	-0.08%	$262.8M	/amrn-vs-imrx →
QTTB Q32 Bio Inc.	C-	61/100	8.9x	—	85.0%	-2.10%	$264.1M	/qttb-vs-imrx →
BCYC Bicycle Therapeutics plc	E	24/100	—	—	-35.0%	-1.55%	$267.4M	/bcyc-vs-imrx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001790340

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immuneering Corporation (Class A) (IMRX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$56.0M, operating cash flow of -$45.3M, and free cash flow of -$45.5M (+17.4% YoY). On the balance sheet, IMRX closed FY2025 with $232.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$56.0M	-$45.3M	-$45.5M	$232.0M	—
FY2024 (FY)	2024-12-31	$0	-$61.0M	-$55.0M	-$55.1M	$52.7M	—
FY2023 (FY)	2023-12-31	$0	-$53.5M	-$49.0M	-$49.0M	—	—

3. IMRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Immuneering Corporation (Class A) (NASDAQ: IMRX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $4.02 (+0.75% 1D, market cap $260.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMRX ranks #481 in composite RQD confidence.

How does IMRX compare to ABEO and AMRN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMRX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ABEO (Abeona Therapeutics Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $260.8M) and AMRN (Amarin Corporation plc) posts a D- grade (43/100 RQD, P/E N/A, ROIC -12.2%, cap $262.8M). Among the 5-stock peer group, QTTB leads on earnings multiple (8.9x) while QTTB leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IMRX?

Per IMRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790340), Immuneering Corporation (Class A) generated $0 in revenue, -$56.0M in net income, and -$45.5M in free cash flow against $232.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IMRX trading relative to its 50-day, 200-day, and 52-week technical levels?

IMRX last traded at $4.02 (+0.75% on volume of 777,079 shares), positioning the stock -6.07% below its 50-day simple moving average ($4.28) and -16.42% below its 200-day simple moving average ($4.81). Across its 52-week range of $3.38 to $8.48, IMRX sits at the 12.5% percentile with a 14-day RSI of 43.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($3.54 to $4.50).

IMRX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell IMRX stock right now?

Immuneering Corporation (Class A) (IMRX) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is IMRX's 12-month price target and RQD AI Jury consensus?

IMRX's 12-month base price target is $3.78 (range $2.95 to $8.9), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: IMRX RQD Cockpit IMRX 12M Forecast IMRX Earnings & Move IMRX Dividends & DRIP IMRX Insiders & 13F IMRX Whale Options IMRX Profit Sankey IMRX News & Why